88 related articles for article (PubMed ID: 2151769)
41. The induction of T cell unresponsiveness by rapidly modulating CD3.
Davis LS; Wacholtz MC; Lipsky PE
J Immunol; 1989 Feb; 142(4):1084-94. PubMed ID: 2521658
[TBL] [Abstract][Full Text] [Related]
42. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes.
Turka LA; Ledbetter JA; Lee K; June CH; Thompson CB
J Immunol; 1990 Mar; 144(5):1646-53. PubMed ID: 2155264
[TBL] [Abstract][Full Text] [Related]
43. Patterns of costimulation of T cell clones by cross-linking CD3, CD4/CD8, and class I MHC molecules.
Wacholtz MC; Patel SS; Lipsky PE
J Immunol; 1989 Jun; 142(12):4201-12. PubMed ID: 2470819
[TBL] [Abstract][Full Text] [Related]
44. Basis for differing biological immunosuppressive potencies of monoclonal and polyclonal T cell antibodies.
Sherburne CG; Condie RM; Onyekaba CO
Transplant Proc; 1989 Feb; 21(1 Pt 1):1036-9. PubMed ID: 2523113
[No Abstract] [Full Text] [Related]
45. Prophylactic use of the new monoclonal antibody BMA 031 in clinical kidney transplantation.
Smely S; Weschka M; Hillebrand G; Dendorfer U; Krombach F; Kurrle R; Land W; Hammer C
Transplant Proc; 1990 Aug; 22(4):1785-6. PubMed ID: 2143862
[No Abstract] [Full Text] [Related]
46. Experience with OKT3 after orthotopic liver transplantation.
Stratta R; Shaefer M; Bradshaw K; Wood R; Langnas A; Zetterman R; Donovan J; Sorrell M; Markin R; Shaw BW
Transplant Proc; 1991 Jun; 23(3):1970. PubMed ID: 1829556
[No Abstract] [Full Text] [Related]
47. In vivo use of OKT3: main issues for the monitoring of treated patients.
Chatenoud L; Ferran C; Bach JF
Transplant Proc; 1990 Dec; 22(6):2605-8. PubMed ID: 2124743
[No Abstract] [Full Text] [Related]
48. The importance of non-human primates for preclinical testing of immunosuppressive monoclonal antibodies.
Jonker M
Semin Immunol; 1990 Nov; 2(6):427-36. PubMed ID: 2104280
[TBL] [Abstract][Full Text] [Related]
49. Downregulation of antigen-presenting cell functions after administration of mitogenic anti-CD3 monoclonal antibodies in mice.
Muraille E; Andris F; Pajak B; Wissing KM; De Smedt T; Desalle F; Goldman M; Alegre ML; Urbain J; Moser M; Leo O
Blood; 1999 Dec; 94(12):4347-57. PubMed ID: 10590081
[TBL] [Abstract][Full Text] [Related]
50. [New strategies for the development of tolerance following organ transplantation].
Kabelitz D
Dtsch Med Wochenschr; 1997 Jul; 122(28-29):879-81. PubMed ID: 9264917
[No Abstract] [Full Text] [Related]
51. Modulation of the CD4 molecule is a major event in the induction of transplantation tolerance with anti-CD4 monoclonal antibodies.
Saitovitch D; Bushell A; Morris PJ; Wood KJ
Transplant Proc; 1997; 29(1-2):1159. PubMed ID: 9123250
[No Abstract] [Full Text] [Related]
52. [Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes].
Chatenoud L
Med Sci (Paris); 2006 Jan; 22(1):5-6. PubMed ID: 16386207
[No Abstract] [Full Text] [Related]
53. New generation CD3 monoclonal antibodies: are we ready to have them back in clinical transplantation?
You S; Chatenoud L
Curr Opin Organ Transplant; 2010 Dec; 15(6):720-4. PubMed ID: 20881491
[TBL] [Abstract][Full Text] [Related]
54. Fine tuning of antigen-presenting cell-directed monoclonal antibody strategies in the induction of human allospecific T-cell tolerance in vitro.
Koenen HJ; Joosten I
Transplant Proc; 1998 Aug; 30(5):2447-9. PubMed ID: 9723532
[No Abstract] [Full Text] [Related]
55. The new immunosuppression.
Waldmann H
Curr Opin Chem Biol; 2003 Aug; 7(4):476-80. PubMed ID: 12941422
[TBL] [Abstract][Full Text] [Related]
56. Immune regulation.
Weigle WO
J Reticuloendothel Soc; 1975 Mar; 17(3):179. PubMed ID: 1079254
[No Abstract] [Full Text] [Related]
57. Immunosuppression in atherosclerosis: mobilizing the opposition within.
Goronzy JJ; Weyand CM
Circulation; 2006 Oct; 114(18):1901-4. PubMed ID: 17075023
[No Abstract] [Full Text] [Related]
58. Therapeutic immunosuppression of T cells.
Waldmann H; Cobbold SP; Wraith D; Isaacs J
Curr Opin Biotechnol; 1992 Dec; 3(6):668-74. PubMed ID: 1369123
[TBL] [Abstract][Full Text] [Related]
59. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.
Ilan Y; Shailubhai K; Sanyal A
Clin Exp Immunol; 2018 Sep; 193(3):275-283. PubMed ID: 29920654
[TBL] [Abstract][Full Text] [Related]
60. Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesis.
Gianchecchi E; Crinò A; Giorda E; Luciano R; Perri V; Russo AL; Cappa M; Rosado MM; Fierabracci A
PLoS One; 2014; 9(10):e110755. PubMed ID: 25333705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
